Clinical trials: Active Rheumatoid Arthritis
Rheumatoid Arthritis
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
This study is designed to evaluate the effectiveness of adding etanercept to disease modifying anti-rheumatic drug (DMARD) therapy in patients with moderately active Rheumatoid Arthritis (RA).
- Trial name
- NCT01313208
- Testing
- etanercept, DMARD Therapy
- Where
- 47 sites in United States, Canada
- Volunteers
- 210 people
- Sponsor
- Amgen
Arthritis, Rheumatoid
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg BID is safe and effective when used in combination with a variety of traditional disease modifying antirheumatic drugs in adult patients…
- Trial name
- NCT00856544
- Testing
- CP-690,550
- Where
- 133 sites in United States, Australia and 18 more
- Volunteers
- 795 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Re³ (Re-Cube: Retain Remicade® Response)(Study P04249AM3)
This Phase IIIb, randomized, multi-national, multi-center, blinded study of Infliximab (IFX) in subjects aged 18 and older with active RA is being conducted to assess whether increasing either the infusion dose or infusion…
- Trial name
- Re³ (NCT00394589)
- Testing
- Infliximab Increased Frequency, Infliximab Increased Dose, Infliximab Control
- Volunteers
- 43 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
This is a Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety between CT-P13 SC and CT-P13 IV in Patients with Active Rheumatoid Arthritis (RA).
- Trial name
- NCT03147248
- Testing
- CT-P13
- Where
- South Korea
- Volunteers
- 407 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Clinical Outcomes, Compliance and Effectiveness of Switching From Infliximab or Etanercept to Adalimumab in Patients With Active Rheumatoid Arthritis (RA). A Multicenter Post-Marketing Observational Study in Routine Clinical Use
This is a prospective, single-arm, post marketing observational study in adult patients with active rheumatoid arthritis (RA) who are discontinuing treatment due to lack of efficacy, intolerance or to an incomplete response with…
- Trial name
- FALLA (NCT01083160)
- Where
- 12 sites in Mexico
- Volunteers
- 82 people
- Sponsor
- Abbott
Rheumatoid Arthritis
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment
This open-label, multi-center study in a local environment will evaluate the safety and the effect on disease activity with regard to reduction in signs and symptoms over 6 months of treatment in patients with moderate to severe…
- Trial name
- NCT01254331
- Testing
- tocilizumab [RoActemra]
- Where
- 6 sites in Tunisia
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
To assess comparative radiographic efficacy, clinical efficacy and safety of etanercept (ETN) + methotrexate (MTX) with usual disease-modifying anti-rheumatic drug (DMARD) treatment in subjects with moderate RA who were treated…
- Trial name
- NCT00706797
- Testing
- etanercept (EnbrelTM), methotrexate
- Where
- 45 sites in Czechia, France and 7 more
- Volunteers
- 141 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 Without Coadministration of Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objectives of this study are to verify the superiority in efficacy (American College of Rheumatology 20%: ACR20) and investigate the pharmacokinetics and safety of CDP870 versus placebo without coadministration of MTX in…
- Trial name
- NCT00791921
- Testing
- CDP870
- Where
- 7 sites in Japan
- Volunteers
- 230 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Rheumatoid Arthritis (RA)
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function.
- Trial name
- NCT04888585
- Testing
- ABBV-154
- Where
- 220 sites in United States, Australia and 19 more
- Volunteers
- 473 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone
The primary objectives of this study are to compare the efficacy, safety, and tolerability of upadacitinib 30 mg once daily (QD) and 15 mg QD versus placebo for the treatment of signs and symptoms of adults with moderately to…
- Trial name
- SELECT-NEXT (NCT02675426)
- Testing
- Upadacitinib
- Where
- 167 sites in United States, Argentina and 36 more
- Volunteers
- 661 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)
Primary Objective: To evaluate the immunogenicity of sarilumab administered as monotherapy. Secondary Objectives: To evaluate the other safety aspects of sarilumab administered as monotherapy.
- Trial name
- SARIL-RA-ONE (NCT02121210)
- Testing
- sarilumab SAR153191 (REGN88)
- Where
- 28 sites in United States, Chile and 5 more
- Volunteers
- 132 people
- Sponsor
- Sanofi
Joint Diseases, Rheumatoid Arthritis
OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis
Being physically active can reduce pain and fatigue, improve mobility and enhance quality of life in people with arthritis, but adherence to an active lifestyle is poor, with less than half of people with arthritis being active.
- Conditions
- Joint Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT02554474
- Testing
- Education, Fitbit/FitViz, physiotherapist counselling., Same intervention with a 9-week delay
- Where
- Canada
- Volunteers
- 118 people
- Sponsor
- University of British Columbia
Rheumatoid Arthritis
Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging
Determine the localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with active RA and concordance with clinical symptomology.
- Trial name
- NCT02683421
- Testing
- Tilmanocept
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Navidea Biopharmaceuticals
Rheumatoid Arthritis
The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis
The purpose of this study is to evaluate the long-term safety and tolerability of CDP6038 (olokizumab) treatment in adult subjects with active rheumatoid arthritis (RA) who completed study RA0083 [NCT01463059].
- Trial name
- NCT01533714
- Testing
- CDP6038 (olokizumab)
- Where
- 32 sites in Japan, South Korea and 1 more
- Volunteers
- 103 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Rheumatoid Arthritis
A Study of Adalimumab When Added to Inadequate Standard Anti-rheumatic Therapy in Patients With Active Rheumatoid Arthritis
A total of 100 participants diagnosed with active rheumatoid arthritis were enrolled at 5 sites in Russia. Adalimumab was administered by subcutaneous injection every other week, with dose escalation to weekly dosing available…
- Trial name
- NCT01231321
- Testing
- adalimumab
- Where
- 5 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Abbott
Rheumatoid Arthritis
TL011 in Severe, Active Rheumatoid Arthritis Patients
The purpose of this study is to determine the safety and pharmacology of TL011 in patients with severe rheumatoid arthritis.
- Trial name
- NCT01123070
- Testing
- TL011, anti CD20, for the treatment of rheumatoid arthritis, MabThera infusions
- Where
- 18 sites in Czechia, Hungary and 3 more
- Volunteers
- 54 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Rheumatoid Arthritis
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
This is a single-arm, multi-center, prospective cohort study (post-marketing observational study). The observation period for each participant is 48 weeks.
- Trial name
- NCT01346488
- Volunteers
- 2,088 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Rheumatoid Arthritis
A Study of CDP870 as Add-on Meditation to Methotrexate (MTX) in Patients With Rheumatoid Arthritis
The objective of this trial is to compare the efficacy of Certolizumab (CZP) (CDP870) in combination with Methotrexate (MTX) to MTX alone in the treatment of signs and symptoms in patients with active rheumatoid arthritis (RA)…
- Trial name
- NCT00993317
- Testing
- CDP870 200mg, Methotrexate
- Where
- 15 sites in South Korea
- Volunteers
- 127 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Arthritis, Rheumatoid
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
The purpose of this study is to assess the efficacy of sirukumab as measured by the reduction of the signs and symptoms of rheumatoid arthritis (RA) in patients with active RA who are unresponsive or intolerant to treatment with…
- Trial name
- NCT01606761
- Testing
- Sirukumab
- Where
- 201 sites in United States, Argentina and 20 more
- Volunteers
- 878 people
- Sponsor
- Janssen Research & Development, LLC
Rheumatoid Arthritis
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Phase IIIb study to determine early response to Certolizumab Pegol (CZP) with Magnetic Resonance Imaging (MRI) score Outcome Measures in Rheumatoid Arthritis (RA) Clinical Trials (OMERACT) RA MRI Scoring System (RAMRIS) in…
- Trial name
- MARVELOUS (NCT01235598)
- Testing
- Certolizumab Pegol (CZP) 200 mg, Certolizumab Pegol (CZP) 400 mg
- Where
- 10 sites in Denmark, Netherlands and 2 more
- Volunteers
- 41 people
- Sponsor
- UCB Pharma